Business Description
Provectus Biopharmaceuticals Inc
NAICS : 325412
SIC : 2836
ISIN : US74373P1084
Total Employee Number:
6Description
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of bioactive synthetic small molecule halogenated xanthenes (HXs). Its flagship HX molecule is named rose bengal sodium (RBS). The company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (API) in all its clinical development and non-clinical research programs. It has one operating and reporting segment, namely, the development of immunotherapy medicines.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.33 | |||||
Equity-to-Asset | -4.26 | |||||
Debt-to-Equity | -0.56 | |||||
Debt-to-EBITDA | -0.77 | |||||
Piotroski F-Score | 5/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -17.6 | |||||
3-Year FCF Growth Rate | -4.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.08 | |||||
9-Day RSI | 46.65 | |||||
14-Day RSI | 46.03 | |||||
3-1 Month Momentum % | -8.15 | |||||
6-1 Month Momentum % | -5.23 | |||||
12-1 Month Momentum % | -16.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.18 | |||||
Quick Ratio | 0.18 | |||||
Cash Ratio | 0.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | -0.97 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -721.56 | |||||
OCF Margin % | -721.56 | |||||
ROA % | -619.6 | |||||
ROIC % | -150.74 | |||||
3-Year ROIIC % | 294.48 | |||||
ROC (Joel Greenblatt) % | -3535.49 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -5.63 | |||||
EV-to-EBITDA | -5.63 | |||||
EV-to-Revenue | 76.73 | |||||
EV-to-FCF | -10.63 | |||||
Earnings Yield (Greenblatt) % | -17.76 | |||||
FCF Yield % | -10.35 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:PVCT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Provectus Biopharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.336 | ||
| EPS (TTM) ($) | -0.011 | ||
| Beta | 1.7003 | ||
| 3-Year Sharpe Ratio | -0.03 | ||
| 3-Year Sortino Ratio | -0.06 | ||
| Volatility % | 40.24 | ||
| 14-Day RSI | 46.03 | ||
| 14-Day ATR ($) | 0.004767 | ||
| 20-Day SMA ($) | 0.057083 | ||
| 12-1 Month Momentum % | -16.66 | ||
| 52-Week Range ($) | 0.038 - 0.09 | ||
| Shares Outstanding (Mil) | 420.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Provectus Biopharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Provectus Biopharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 56 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | 0.06 (-3.45%) | ||
| General meeting for 2026 | 2026-06-18 16:00 | 0.06 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 0.07 (-1.29%) | ||
| Annual report for 2025 | 2026-03-26 | 0.05 (-3.82%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 0.06 (-1.58%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 0.09 (+3.63%) | ||
| General meeting for 2025 | 2025-06-18 16:00 | 0.08 (+4.12%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 0.08 (-9.03%) | ||
| Annual report for 2024 | 2025-03-28 | 0.10 (+9.05%) |
Show
Entries
Provectus Biopharmaceuticals Inc Frequently Asked Questions
What is Provectus Biopharmaceuticals Inc(PVCT)'s stock price today?
The current price of PVCT is $0.06. The 52 week high of PVCT is $0.09 and 52 week low is $0.04.
When is next earnings date of Provectus Biopharmaceuticals Inc(PVCT)?
The next earnings date of Provectus Biopharmaceuticals Inc(PVCT) is 2026-11-13 Est..
Does Provectus Biopharmaceuticals Inc(PVCT) pay dividends? If so, how much?
Provectus Biopharmaceuticals Inc(PVCT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers